美股新聞 標題聯播 · 近 24 小時 348 則 · 31 個來源 · 最新 9/20 04:16
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · BIIB近 30 天 14 則 · 第 1 / 1 頁
- Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
- How AbbVie's Neuroscience Portfolio Has Transformed Over the Years
- LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
- Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades—Which Pharma Stock Has More Upside?
- Hummingbird Bioscience Appoints Dr. James Garner as President
- Lilly Builds Neuroscience into a New Long-Term Growth Driver
- This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
- Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
- Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?
- Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
- Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients
- LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
- Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
- Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
- American Express, Biogen upgraded: Wall Street's top analyst calls
- Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s?
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。